Grifols, SA

GRFS

Equity

ISIN US3984384087 / Valor 19108728

NASDAQ (2024-11-21)

USD 8.54-0.70%

Grifols, SA
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Grifols, SA is a global healthcare company that specializes in the development, production, and distribution of plasma-derived medicines, other biopharmaceuticals, and transfusion medicine solutions. The company plays a critical role in the healthcare sector by providing essential products that support the treatment of rare and chronic conditions. Grifols' offerings include innovative technologies and products for blood typing, specifically the agglutination technique that uses gel in columns for determining blood groups and ensuring transfusion compatibility. Additionally, the company is involved in the production of organic compounds, including amino acids that are vital for various bodily functions and medical treatments. Grifols' commitment to healthcare innovation extends to the preparation of medicines for intravenous use, which can be prepared through reconstitution or by mixing with existing solutions for fluid therapy. With a focus on improving patient outcomes, Grifols continues to be a key player in the healthcare industry, enabling millions of patients worldwide to lead more productive lives through its trusted and innovative solutions.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-10.6%1Y

-28.1%3Y

-61.5%5Y

Performance

69.8%1Y

55.1%3Y

48.7%5Y

Volatility